** Cancer drug developer Sellas Life Sciences Group's
shares rise 3.7% to $1.24
** Co says preclinical data showed its experimental drug, SLS009, demonstrated high efficacy in treating solid cancers with mutations in the ASXL1 gene
** Late last year, U.S. Food and Drug Administration granted SLS009 "orphan drug" status
** Orphan drug status is given to drugs that treat rare conditions, and are protected through a series of government incentives once in market
** Including session's gains, stock has risen 16.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。